Third Eye Diagnostics
Stage
Unattributed | AliveTotal Raised
$250KLast Raised
$250K | 7 yrs agoAbout Third Eye Diagnostics
Third Eye Diagnostics is developing the Cerepress, a first-of-its-kind non-invasive intracranial pressure monitor that gathers information from the patient's eye. The technology is based on one issued patent, one pending patent, and two applications in progress on methods and apparatus that correlate ICP with measurements taken from the blood vessels within the eye. The Cerepress measures blood pressure in the eye's central retinal vein (CRV) which highly correlates to intracranial pressure.
Missing: Third Eye Diagnostics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Third Eye Diagnostics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Third Eye Diagnostics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Third Eye Diagnostics is included in 3 Expert Collections, including Medical Devices.
Medical Devices
8,605 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Health Monitoring & Diagnostics
2,594 items
Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance
Health IT
7,901 items
Third Eye Diagnostics Patents
Third Eye Diagnostics has filed 5 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
1/17/2017 | 9/10/2019 | Neurotrauma, Diseases of the eye and adnexa, Medical equipment, Ventricular System, Ophthalmology | Grant |
Application Date | 1/17/2017 |
|---|---|
Grant Date | 9/10/2019 |
Title | |
Related Topics | Neurotrauma, Diseases of the eye and adnexa, Medical equipment, Ventricular System, Ophthalmology |
Status | Grant |
Latest Third Eye Diagnostics News
Mar 30, 2018
Third Eye Diagnostics POSTED ON Friday, March 30th, 2018 IN RESIDENTS THIRD EYE DIAGNOSTICS is developing Cerepress™, a non-invasive intracranial pressure (ICP) monitor. The monitor gathers pressure measurements externally from the eyes of patients with a head injury or who have suffered a stroke. Existing standard-of-care devices that monitor ICP are invasive and require drilling a hole through the patient’s skull to measure pressure, which can expose patients to significant complications, and poses a significant and preventable cost to the U.S. healthcare system.
Third Eye Diagnostics Frequently Asked Questions (FAQ)
Where is Third Eye Diagnostics's headquarters?
Third Eye Diagnostics's headquarters is located at 116 Research Drive, Bethlehem.
What is Third Eye Diagnostics's latest funding round?
Third Eye Diagnostics's latest funding round is Unattributed.
How much did Third Eye Diagnostics raise?
Third Eye Diagnostics raised a total of $250K.
Who are the investors of Third Eye Diagnostics?
Investors of Third Eye Diagnostics include Ben Franklin Technology Partners of Central & Northern PA.
Who are Third Eye Diagnostics's competitors?
Competitors of Third Eye Diagnostics include Innara Health, Saladax Biomedical, Ativa Medical, BrainScope, HyperMed Imaging, Infrascan, Good Start Genetics, Accriva Diagnostics, MSDx, MEC Dynamics and 16 more.
Compare Third Eye Diagnostics to Competitors
NeuroDx addresses important unmet needs in the neurosurgical market. Their lead product, ShuntCheck, is an aid to the detection offlow in implanted cerebrospinal fluid (CSF) shunts.
Innara Health is developing new feeding technologies to measure and treat infants, children, and adults that struggle with suck, swallow, and breathe coordination. The company's flagship product is the FDA-approved NTrainer System, a neonatal technology that assesses and develops non-nutritive suck skills for newborns and infants born prematurely. Innara aims to help improve infants' time to oral feed and, in turn, decrease the length of their hospital stay. The company was founded in 2006 and is based in Olathe, Kansas.
Pelikan Technologies is dedicated to the development of hand-held diagnostic and monitoring devices capable of improving the screening and management of a variety of medical conditions. In addition to diabetes, the company's versatile technology platform has applications across a range of other medical conditions that involve blood screening and monitoring. Point-of-care testing and diagnostic panel test systems also represent markets that can benefit from Pelikan's technology. The Pelikan Sun can improve the quality of life for people with diabetes by combining several of the company's technologies into the most convenient and effective blood glucose self-monitoring device available. Pelikan's line of diabetes management tools will address the pain and inconvenience that has stymied the industry's manufacturers, and plagued people with diabetes, contributing to poor blood glucose monitoring compliance. By targeting these barr
MEC Dynamics is a medical devices company developing and manufacturing point-of-care diagnostic products, using its proprietary technology. The company's devices have been designed for use in the both physician's office as well as the patient's home. They enable the 'real time' measurement of key blood analytes for early detection and more effective management of a variety of diseases including diabetes, cardiovascular diseases and cancer. Chronic and life-threatening diseases occurring in both industrial and developing countries could be better treated through early detection and proper monitoring. MEC aims to be a global developer and manufacturer of point-of-care diagnostic products using its technology platform. MEC's lead product, AvieA1c, is FDA 510K approved and NGSP certified.
EyeSense develops an ophthalmic diagnostics system which can measure glucose levels without sampling blood. It is based on measuring the glucose in the interstitial fluid below the conjunctiva of the eye using a hand-held optical read-out device.
InfraScan is developing handheld screening devices for patients in two areas: stroke and traumatic brain injury. The company's flagship product, the Infrascanner handheld imaging device, uses near infrared (NIR) light to screen for intracranial bleeding in patients with head trauma. The results of screening can be used to expedite high-risk patients for CT scanning or surgical intervention.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.